GlassScriptPhysician profile
Carlos M Tejeda
NPI 1366574725
$6,589.05
in general payments reported to CMS, 2019-2025
30 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $685 · 2021: $1,386 · 2022: $1,074 · 2023: $801 · 2024: $1,092 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,840 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.43 |
| Education | $106.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,413.29 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Eli Lilly Export S.A. Puerto Rico Branch | $841.19 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $837.81 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Janssen Pharmaceuticals, INC | $350.26 | 2019-2024 | Rybrevant |
| Janssen Biotech, INC. | $348.93 | 2019-2023 | Erleada |
| Genzyme Corporation | $347.84 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $344.30 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Abbvie INC. | $297.77 | 2021-2025 | Venclexta |
| Pbg Puerto Rico LLC | $216.24 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $174.92 | 2022-2025 | |
| Sobi, INC | $150.16 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $126.59 | 2021-2024 | Rezlidhia, Tavalisse |
| Amgen INC. | $124.58 | 2020-2024 | Xgeva, Kyprolis |
| Fennec Pharmaceuticals, INC. | $115.73 | 2025 | Fyarro |
| Pfizer INC. | $111.95 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $88.42 | 2019-2023 | Perjeta, Tecentriq, Kadcyla |
| Pharmaessentia USA Corporation | $80.45 | 2022-2025 | Besremi |
| Clovis Oncology, INC. | $74.30 | 2021-2022 | |
| Beigene USA, INC. | $72.87 | 2024-2025 | Brukinsa |
| Astellas Pharma US INC | $68.93 | 2021-2022 | |
| Lilly USA, LLC | $66.06 | 2021-2023 | Jardiance |
| Glaxosmithkline, LLC. | $55.44 | 2022-2024 | Jemperli, Ojjaara, Zejula |
| Beone Medicines USA, INC. | $49.53 | 2025 | Brukinsa |
| Tempus Ai, INC | $44.50 | 2025 | Xt Cdx |
| Exelixis INC. | $43.36 | 2025 | Cabometyx |
| Eisai INC. | $43.12 | 2019 | |
| Lantheus Medical Imaging, INC. | $42.94 | 2019-2020 | |
| Taiho Oncology, INC. | $22.25 | 2021 | |
| Incyte Corporation | $21.22 | 2023 | Jakafi |
| Bayer Puerto Rico INC. | $14.10 | 2025 | Stivarga, Nubeqa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Tejeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.